Description:TECHNICAL FIELD:
[001] The present disclosure relates to field of cosmetic composition in general. Particularly, the present disclosure relates to a cosmetic composition for inducing hair growth. More particularly, it relates to a topical cosmetic composition for inducing hair growth containing natural and synthetic actives and the method of preparation thereof.

BACKGROUND:
[002] The hair serves a crucial purpose by shielding the scalp from harmful UV rays and various external factors. Unfortunately, alopecia affects both men and women, and the prevalence of this condition is rising in today's world, largely due to factors such as environmental pollution and an unhealthy balance between stress, work, and personal life.

[003] The existing cosmetic products for hair loss or hair growth on the market, such as tonics, creams, hair oils, and gels, utilize various actives like antioxidants, anti-inflammatory agents, vasodilators, and preservatives. However, these product formulations do not disclose a unique combination of actives that work together to enhance hair growth, even at low concentrations.

[004] Therefore, there is a pressing need to create an effective cosmetic formulation that incorporates such a combination of actives and their derivatives to achieve a synergistic effect on hair growth. Hence, the present disclosure provides an effective cosmetic composition that overcomes the drawbacks of the existing products.

OBJECTIVES
[005] The primary objective of the present disclosure is to provide a topical cosmetic composition.
[006] Another objective of the present disclosure is to provide a topical cosmetic composition for inducing hair growth.
[007] Another objective of the present disclosure is to provide a method for preparing the topical cosmetic composition for inducing hair growth.

SUMMARY
[008] This summary is provided to introduce a selection of concepts in a simplified manner that is described elaborately in detailed description. This summary is neither intended to identify key or essential inventive concepts of the present disclosure nor is it intended to determine the scope of the present disclosure.

[009] In an aspect of the present disclosure , there is provided a topical cosmetic composition comprising: 0.01% to 5% v/v of caffeine; 0.01% to 5% v/v of diaminopyrimidine oxide; 0.001 % to 30%v/v of a methi extract; 1% to 3% v/v of saw palmetto extract; 1% to 5% v/v of vasodilator; and 1 to 3% v/v gallic acid.

[0010] In another aspect of the present disclosure, there is provided a process for preparing the topical cosmetic composition, the process involves the steps of: dissolving diaminopyrimidine oxide in propylene glycol to obtain a first mixture; dissolving caffeine, of arginine to 1/3 rd part of water to the first mixture to obtain a second mixture; dissolving saw palmetto extract into the second mixture to obtain a third mixture; diluting the methi extract with 1/3rd part of water and adding the diluted methi extract to the third mixture with stirring to obtain a fourth mixture; adding gallic acid to the fourth mixture to obtain a fifth mixture; adding of ethanol at a pH in a range of 4.3 to 4.4 to the fifth mixture and adjusting the pH to 5.5; and adding 1/3 rd of water to the pH adjusted mixture to obtain a topical composition.

DETAILED DESCRIPTION:

[0011] For the purpose of promoting an understanding of the principles of the disclosure, reference will now be made to the embodiment illustrated in the drawings and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the disclosure is thereby intended, such alterations and further modifications in the illustrated system, and such further applications of the principles of the disclosure as illustrated therein being contemplated as would normally occur to one skilled in the art to which the disclosure relates. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skilled in the art to which this disclosure belongs. The system, methods, and examples provided herein are illustrative only and not intended to be limiting.

[0012] Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

[0013] It must be noted that as used herein and in the appended claims, the singular forms "a", "and", and "the" include plural referents unless the context dictates otherwise. Thus, for example, reference to "a compound" includes a plurality of such compounds, and reference to "the step" includes reference to one or more steps and equivalents thereof known to those skilled in the art, and so forth.

[0014] The term “some” as used herein is defined as “none, or one, or more than one, or all.” Accordingly, the terms “none,” “one,” “more than one,” “more than one, but not all” or “all” would all fall under the definition of “some.” The term “some embodiments” may refer to no embodiments or to one embodiment or to several embodiments or to all embodiments. Accordingly, the term “some embodiments” is defined as meaning “no embodiment, or one embodiment, or more than one embodiment, or all embodiments.”

[0015] The terminology and structure employed herein is for describing, teaching and illuminating some embodiments and their specific features and elements and does not limit, restrict or reduce the spirit and scope of the claims or their equivalents.

[0016] More specifically, any terms used herein such as but not limited to “includes”, “comprises”, “has”, “consists” and grammatical variants thereof is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. The specification will be understood to also include embodiments which have the transitional phrase “consisting of” or “consisting essentially of” in place of the transitional phrase “comprising.” The transitional phrase “consisting of” excludes any element, step, or ingredient not specified in the claim, except for impurities associated therewith. The transitional phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps “and those that do not materially affect the basic and novel characteristic(s)” of the claimed disclosure.

[0017] Whether or not a certain feature or element was limited to being used only once, either way it may still be referred to as “one or more features” or “one or more elements” or “at least one feature” or “at least one element.” Furthermore, the use of the terms “one or more” or “at least one” feature or element does NOT preclude there being none of that feature or element, unless otherwise specified by limiting language such as “there NEEDS to be one or more” or “one or more element is REQUIRED.”

[0018] As used herein, the term “about” is used to indicate a degree of variation or tolerance in a numerical or quantitative value. It indicates that the disclosed value is not intended to be strictly limiting, and may vary by plus or minus 5%, without departing from the scope of the present disclosure.

[0019] Unless otherwise defined, all terms, and especially any technical and/or scientific terms, used herein may be taken to have the same meaning as commonly understood by one having an ordinary skill in the art.

[0020] Reference is made herein to some “embodiments.” It should be understood that an embodiment is an example of a possible implementation of any features and/or elements presented in the attached claims. Some embodiments have been described for the purpose of illuminating one or more of the potential ways in which the specific features and/or elements of the attached claims fulfil the requirements of uniqueness, utility and non-obviousness.

[0021] Use of the phrases and/or terms such as but not limited to “a first embodiment,” “a further embodiment,” “an alternate embodiment,” “one embodiment,” “an embodiment,” “multiple embodiments,” “some embodiments,” “other embodiments,” “further embodiment”, “furthermore embodiment”, “additional embodiment” or variants thereof do NOT necessarily refer to the same embodiments. Unless otherwise specified, one or more particular features and/or elements described in connection with one or more embodiments may be found in one embodiment, or may be found in more than one embodiment, or may be found in all embodiments, or may be found in no embodiments. Although one or more features and/or elements may be described herein in the context of only a single embodiment, or alternatively in the context of more than one embodiment, or further alternatively in the context of all embodiments, the features and/or elements may instead be provided separately or in any appropriate combination or not at all. Conversely, any features and/or elements described in the context of separate embodiments may alternatively be realized as existing together in the context of a single embodiment.

[0022] The present disclosure discloses a topical cosmetic composition comprising caffeine; diaminopyrimidine oxide; methi extract; saw palmetto extract; vasodilator; and gallic acid.

[0023] In an embodiment of the present disclosure, there is provided a topical cosmetic composition comprising 0.01% to 5% v/v of caffeine; 0.01% to 5% v/v of diaminopyrimidine oxide; 0.001 % to 30%v/v of a methi extract; 1% to 3% v/v of saw palmetto extract; and 1% to 5% v/v of vasodilator; and 1 to 3% v/v gallic acid.

[0024] In another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the composition further comprises excipients and solvents, wherein the solvents are selected from group comprising of water, alcohol, ether and ketone or combinations thereof.

[0025] In yet another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the composition further comprises 5-alpha reductase inhibitor and is selected from trigonelline, finasteride, dutasteride, or combinations thereof.

[0026] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the saw palmetto extract comprises polyphenols, wherein the polyphenols are selected from the group comprising of gallic acid, tannic acid, ellagic acid, and epigallocatechin gallate, or combinations thereof.

[0027] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the methi extract comprises alkaloids, wherein the alkaloids are selected from the group comprising of trimethylamine, neurin, trigonelline, choline, gentianine, carpaine, and betain or combination thereof, wherein the trigonelline is present in a range from 0.03% to 1% v/v of methi extract.

[0028] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the vasodilator is selected from the group comprising of arginine, methyl salicylate, and menthol, or combinations thereof.

[0029] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the diaminopyrimidine oxide and caffeine is present in a ratio of 0.002: 500 and wherein the methi extract and the vasodilator are present in a ratio of 0.0002: 30.

[0030] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the excipients are selected from the group comprising of a humectant, a preservative, a conditioning agent, a surfactant, a perfume, oil, emollient, antidandruff agent, antioxidants, plasticizers, polymers, binders, preservatives, color, emotive, pH regulator, secondary emulsifier, electrolytes conditioners, and solubilizers, or combinations thereof.

[0031] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the humectant is selected from the group comprising of glycerin/glycerol, sorbitol, and propylene glycol, or combinations thereof.

[0032] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the preservative is selected from the group consisting of ethylhexylglycerin, phenoxyethanol, methylisothiazolinone, ethyl alcohol, BHT, and hydantoin, or combinations thereof.

[0033] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the conditioning agent is selected from PEG 12 dimethicone and cyclomethicone, wherein the surfactant is selected from the group comprising of amphoteric surfactants, ionic surfactants, and non-ionic surfactants.

[0034] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the emollient is selected from the group comprising of shea butter, mineral oil, jojoba oil, squalane, dimethicone, ceramides, caprylic/capric triglyceride, glycerol, and IPM, or combinations thereof.

[0035] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the antidandruff agent is selected from the group comprising of Zinc Pyrithione, Piroctone Olamine, Ketoconazole, Tropolone, Hinokitol, Selenium Sulfide, Salicylic Acid, Climbazole, Sodium Salicylate, Ciclopiroxolamine, lchtammol, Sulfur, Clotrimazole, Crotamiton, Zinc Salicylate, Lactic Acid, Chlorohexidine Digluconate, Phenoxyisopropanol, Isopropanol, Farnesol, Glycolic Acid, Tannic acid, Alcohol, Triclosan, Zinc Gluconate, Zinc PCA, Camphor, Aluminium salts, Sodium Lactate, Polyaminopropyl Biguanide, Zinc Acetate, Triethyl Citrate, Ethylhexylglycerol, Aluminium Circonium, Tetrachlorohydrex GLY, Pentetic Acid, Diisopropylamine Aminoethylpropanol, Zinc Ricinoleate, Aluminium Sesquichlorohydrate, imidazole derivatives, glycolic acid, steroids, climbazole, and the derivatives.

[0036] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the antioxidant is selected from the group comprising of Citric acid, Ascorbic Acid, TBHQ, BHT, Vit. E, Coenzyme Q10, Niacinamide, Retinoids, Polyphenols, flavonoids, flavanols, stilbens, and terpenes.

[0037] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the plasticizer is selected from group comprising of stearic acid, triglycerides; fatty acids, their esters and their alkanolamines or combinations thereof.

[0038] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the polymers are selected from the group comprising of silicone polymers, water soluble polymers, anionic, zwitterionic, amphoteric, and non-ionic polymers or combinations thereof.

[0039] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the binders are selected from the group comprising of high molecular weight polyethylene glycols (PEGs), poly acrylates, high molecular weight polyox, silicates, fatty alcohols, lanolin, sugars, and tallow alcohol ethoxylates, or combinations thereof.

[0040] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the pH regulator is selected from the group comprising of citric acid, lactic acid, oxalic acid, acetic acid, triethanolamine, and sulphuric acid, or combinations thereof.
[0041] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the conditioners are selected from the group comprising of silicones, and polyquats or combinations thereof.

[0042] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the solubilizers can be selected from, PEG/PPG 18/18 dimethicone, PEG-3 dimethicone, PEG 12 dimethicone, PEG 10 dimethicone, PEG 60/35/40/n hydrogenated castor oil, oleth-5, C12-15 Alkyl Benzoate, Dibutyl Adipate, Dicaprylyl Carbonate, Propylheptyl Caprylate, Capramide DEA, Potassium Caprylate, Potassium Caprylate/caprate, Arlatone 975, Oleth-2, PEG 75 lanolin, Octoxynol-11, Lauryl PEG-9 Polydimethylsiloxyethyl 8 dimethicone, Isoceteth-20 and PEG-7 Olivate, or combinations thereof.

[0043] In still another embodiment of the present disclosure, there is provided a topical cosmetic composition, as described herein, wherein the composition is formulated in a form selected from an oil, a creme, a biphasic, a gel, a solution, a suspension, a dispersion, an emulsion, a micro-formulation, a nano formulation, a nano carrier, a lipid-based system, a colloidal dispersion, a polymer-based system, or a lotion.

[0044] In still another embodiment of the present disclosure, there is provided a process for preparing the topical composition, wherein the process involves the steps of: dissolving diaminopyrimidine oxide in propylene glycol to obtain a first mixture; dissolving caffeine, of arginine to 1/3 rd part of water to the first mixture to obtain a second mixture; dissolving saw palmetto extract into the second mixture to obtain a third mixture; diluting the methi extract with 1/3rd part of water and adding the diluted methi extract to the third mixture with stirring to obtain a fourth mixture; adding gallic acid to the fourth mixture to obtain a fifth mixture; adding of ethanol at a pH in a range of 4.3 to 4.4 to the fifth mixture and adjusting the pH to 5.5; and adding 1/3 rd of water to the pH adjusted mixture to obtain a topical composition.

EXAMPLES
Example 1:
A topical cosmetic composition is prepared having ingredients as a tonic composition (Diaminopyrimidine oxide and Caffeine are in a ratio of 0.002 and the alkaloid and the vasodilator are in a ratio of 0.0002)

Table 1 – Tonic composition I
Sr.No. INCI Name %V/V
1 Water 52.089
2 Caffeine 5
3 Diaminopyrimidine oxide 0.01
4 Trigonelline Hydrochloride 0.001
5 Saw palmetto extract 2
6 Gallic acid 2
7 Arginine 5
8 Propylene glycol 10
9 Ethyl alcohol 14.5
10 Glycerol 5
11 PEG-12 Dimethicone 2
12 Polysorbate 80 0.8
13 Perfume 0.8
14 Ethylhexylglycerin (and) phenoxyethanol 0.8
Total 100

Example 2
A topical cosmetic composition is prepared having ingredients as a tonic composition (Diaminopyrimidine oxide and Caffeine are in a ratio of 500 and the alkaloid and the vasodilator are in a ratio of 0.15)
Table 2 – Tonic composition II
Sr.No. INCI Name %V/V
1 Water 55.94
2 Caffeine 0.01
3 Diaminopyrimidine oxide 5
4 Trigonelline Hydrochloride 0.15
5 Saw palmetto extract 2
6 Gallic acid 2
7 Arginine 1
8 Propylene glycol 10
9 Ethyl alcohol 14.5
10 Glycerol 5
11 PEG-12 Dimethicone 2
12 Polysorbate 80 0.8
13 Perfume 0.8
14 Ethylhexylglycerin (and) phenoxyethanol 0.8
Total 100

Example 3
A topical cosmetic composition is prepared having ingredients as a tonic formulation (Higher 5 alpha reductase inhibitor concentration, Methi seed extract as source of alkaloid, Tannic acid as polyphenol).
Table 3 – Tonic composition III
Sr.No. INCI Name %V/V
1 Water 26
2 Caffeine 5
3 Diaminopyrimidine oxide 0.1
4 Methi Seed Extract 30
5 Saw palmetto extract 2
6 Tannic acid 2
7 Methyl salicylate 1
8 Propylene glycol 10
9 Ethyl alcohol 14.5
10 Glycerol 5
11 PEG-12 Dimethicone 2
12 Polysorbate 80 0.8
13 Perfume 0.8
14 Ethylhexylglycerin (and) phenoxyethanol 0.8
Total 100

Example 4
A topical cosmetic composition is prepared having ingredients as a cream composition
Table 4 - Cream Formulation
Sr.No. Ingredients % (w/w)
1 Propylene Glycol 3
2 Polysobate 80 1.4
3 Methyl Paraben 0.3
4 Choline chloride 0.05
5 Trigonelline hydrochloride 0.1
6 Arginine 1
7 Acrylates/C10-30 Alkyl Acrylate Crosspolymer 0.22
8 Isopropyl myristate 20
9 Caffeine 2
10 Diaminopyrimidine oxide 1
11 Gallic acid 2.5
12 Epigallocatechin gallate 0.5
13 Sorbitan Oleate 2
14 Propyl Paraben 0.1
15 Glyceryl Stearate 1
16 Cetyl alcohol 1.5
17 Butylated hydroxytoluene 0.05
18 Amodimethicone/Morpholinomethyl Silsesquioxane (and) Trideceth-5 (and) Glycerin 3
19 Triethanol amine 0.18
20 Phenoxyethanol 0.25
21 Perfume 1
22 Distilled Water 58.85
Total 41.15

Example 5: Scalp Care Composition

Table 5 - Scalp Care Composition
Sr. No. INCI Name %v/v
1 Water 52.089
2 Caffeine 5
3 Diaminopyrimidine oxide 0.01
4 Trigonelline Hydrochloride 0.001
5 Saw palmetto extract 2
6 Gallic acid 2
7 Arginine 5
8 Propylene glycol 10
9 Ethyl alcohol 13.5
10 Glycerol 5
11 Climbazole 0.5
12 Piroctone Olamine 0.5
13 PEG-12 Dimethicone 2
14 Polysorbate 80 0.8
15 Perfume 0.8
16 Ethylhexylglycerin (and) phenoxyethanol 0.8
Total 100

Example 6 -Alpha Reductase inhibition Assay
[0045] The ELISA assay works on the Sandwich ELISA principle. The 96-well plate is pre-coated with capture antibody. Different concentrations of standards and unknown samples containing the antigen(5-α-reductase) is added to the plate. Detection antibody conjugated to Biotin is added which binds to the antigen. An HRP is then added which binds to the biotin. The TMB substrate added reacts with the HRP and develops colour. Sulfuric acid (Stop solution) added to the wells to terminate the colour development reaction, and the absorbance is measured at 450nm. The concentration of the unknown sample can be calculated by comparing its OD value with known OD values obtained on the standard curve to determine the concentration of the antigen (5-α reductase). PC3- prostate cancer Cell line, Human 5-alpha reductase / SRD5A2 ELISA Kit (Sandwich ELISA) by LSBio Inc. (USA).

[0046] The assay was performed using manufacturer’s instructions for quantification of 5-α-reductase. The OD was measured at 450nm using the Cytation 3 microplate reader and analysed with Gen 5.0 software.
Table 6 - % Reduction of 5-Alpha Reductase
Sample Description % Reduction of 5-AR

Positive Control – Finasteride 100.00
Negative Control – Testosterone 0.00
Methi Extract 27.23
Trigoneline Hydrochloride 45.56
Caffeine 84.47
Saw Palmetto Extract 30.00
Gallic Acid 78.15
Tannic Acid 81.84
Epigallocatechin gallate 45.00
Diaminopyrimidine oxide 61.00
Arginine 20.53
Menthol 62.80
Diaminopyrimidine oxide + Trigonelline Hydrochloride + Saw Palmetto Extract + Arginine + Gallic Acid 94.34
Diaminopyrimidine oxide + Methi Extract + Saw Palmetto Extract + Arginine + Gallic Acid 92.65

The reduction of 5-Alpha Reductase indicates potential for hair growth. Therefore, it can be seen from the table that the hair growth composition of the present disclosure shows better potential for hair growth than the individual ingredients and is comparable to the positive control.

Example 7 : Cell Proliferation by BrdU Assay:
[0047] The highest non-cytotoxic concentration was tested for cell-proliferation of dermal papilla cells. % of cells proliferated were calculated basis comparison with untreated cells post 24 hours incubation with test substance at the highest NCC. Insulin is taken as a positive control and SDS (Sodium Dodecyl Sulfate) is used as a negative control. Cells were seeded in Duplicates.

[0048] Seed 1 x 104 cells per well were placed in a 96 well plate with the respective media for that particular cell line and allowed to grow for approximately for 24 hours for attachment in the incubator 10 at 37⁰C and 5% CO2. The media was replaced after with fresh complete media containing fixed concentrations of test substances/actives/extract, to a final volume of 100 μL/ well. The plates were then incubated in a humidified atmosphere at 37°C and 5% CO2 for next 24h.

[0049] To check the cell proliferation, BrdU labelling solution was prepared from stock, where the Brdu labelling solution stock contains media (1:100). To each well 100μL of this media was added and incubated at 37°C and 5% CO2 for next 4h.

[0050] The labelling medium was removed from adherent cells by tapping off or pipetting out using 200μL pipette. – for suspension cells, centrifuge the microplate at 1000 rpm for 5 minutes in the centrifuge, then flick off or aspirate by pipetting. To the cells 200 μL/well FixDenat (Bottle 2) was added using the 200μL pipette and incubated for 20 minutes to 30 minutes at +15 °C to 25°C (RT). FixDenat solution was removed thoroughly by flicking off and tapping. Anti-BrdU-POD working solution of 100 μL/well was added using the 100μL pipette and tips and incubated for approximately 90 minutes at 15 to 25°C.

[0051] Removing the Anti-Brdu-POD working solution by flicking off and rinse wells three times with 200 μL/well using the multichannel pipette and the 200μL pipette.1X washing buffer (Prepare this from provided 10 X washing buffer and removing the washing solution by tapping or aspirate using pipette.

[0052] Adding100 μL/well Substrate Solution and incubating at +15 to +25°C (RT) until color 30 development is sufficient for photometric detection for 20mins and adding 25 μl 1M H2SO4 (stop solution) to each well mix thoroughly by pipetting. The absorbance of the samples was measured in an ELISA reader at 450 nm with 30s of shaking in the software protocol.

[0053] The cell proliferation was calculated using OD values of test with untreated sample.
Table 8 - Cell Proliferation by BrdU Assay

Sample Description UV-Vis Absorbance Avg %cell proliferation
OD1 OD2
Untreated 2.431 2.457 2.444 100.000
Positive Control – Insulin 3.574 3.158 3.366 137.725
Negative Control - Sodium dodecyl sulfate 0.225 0.213 0.219 8.961
Methi Extract 2.741 2.683 2.712 110.966
Trigonelline Hydrochloride 2.723 2.759 2.741 112.152
Caffeine 2.794 2.746 2.770 113.339
Saw Palmetto Extract 2.755 2.721 2.738 112.029
Gallic Acid 2.717 2.754 2.736 111.927
Tannic Acid 2.641 2.705 2.673 109.370
Epigallocatechin gallate 2.768 2.638 2.703 110.597
Diaminopyrimidine oxide 2.841 2.970 2.906 118.883
Arginine 2.847 2.764 2.806 114.791
Menthol 2.788 2.793 2.791 114.178
Diaminopyrimidine oxide + Trigonelline Hydrochloride + Saw Palmetto Extract + Arginine + Gallic Acid 3.011 3.251 3.131 128.110
Diaminopyrimidine oxide + Methi Extract + Saw Palmetto Extract + Arginine + Gallic Acid 3.111 3.251 3.181 130.155
Diaminopyrimidine oxide+Epigallocatechin gallate 2.761 2.848 2.8045 114.75
Diaminopyrimidine oxide+Methi Extract 3.041 2.930 2.9855 122.16
Diaminopyrimidine oxide+Saw Palmetto Extract 2.717 2.98 2.8485 116.55
Diaminopyrimidine oxide+Arginine 2.645 2.951 2.798 114.48
Diaminopyrimidine oxide+Triginelline Hydrochloride 2.762 3.016 2.889 118.21
Diaminopyrimidine oxide+Tannic Acid 2.168 2.711 2.4395 99.82
Diaminopyrimidine oxide+Caffeine 2.654 2.221 2.4375 99.73
Diaminopyrimidine oxide+Gallic acid 1.954 2.156 2.055 84.08
Arginine 1.89 2.111 2.0005 81.85
Tannic acid 2.129 1.819 1.974 80.77
Gallic acid 1.846 1.733 1.7895 73.22
Epigallocatechin gallate 2.003 2.036 2.0195 82.63

Higher the BrdU cell proliferation, better is the potential for hair growth. Therefore, it can be seen from the table that the hair growth composition of the present disclosure shows better potential for hair growth than the individual ingredients.
, Claims:
1. A topical cosmetic composition comprising:
i. 0.01% to 5% v/v of caffeine;
ii. 0.01% to 5% v/v of diaminopyrimidine oxide;
iii. 0.001 % to 30% v/v of methi extract;
iv. 1% to 3% v/v of saw palmetto extract
v. 1% to 5% v/v of vasodilator; and
vi. 1 to 3% v/v of gallic acid.

2. The composition as claimed in claim 1, wherein the composition further comprises excipients and solvents and wherein the solvents are selected from group comprising of water, alcohol, ether and ketone or combinations thereof.

3. The composition as claimed in claim 1, wherein the composition further comprises 5-alpha reductase inhibitor and is selected from trigonelline, finasteride, dutasteride, or combinations thereof.

4. The composition as claimed in claim 1, wherein the saw palmetto extract comprises polyphenols and wherein the polyphenols are selected from the group comprising of gallic acid, tannic acid, ellagic acid, and epigallocatechin gallate, or combinations thereof.

5. The composition as claimed in claim 1, wherein the methi extract comprises alkaloids, wherein the alkaloids are selected from the group comprising of trimethylamine, neurin, trigonelline, choline, gentianine, carpaine, and betain or combination thereof and wherein the trigonelline is present in a range from 0.03% to 1% v/v of methi extract.

6. The composition as claimed in claim 1, wherein the vasodilator is selected from the group comprising of arginine, methyl salicylate, and menthol, or combinations thereof.

7. The composition as claimed in claim 1, wherein the diaminopyrimidine oxide and caffeine is present in a ratio of 0.002 : 500 and wherein the methi extract and the vasodilator are present in a ratio of 0.0002 : 30.

8. The composition as claimed in claim 1, wherein the composition is formulated in a form selected from an oil, a creme, a biphasic, a gel, a solution, a suspension, a dispersion, an emulsion, a micro-formulation, a nano formulation, a nano carrier, a lipid-based system, a colloidal dispersion, a polymer-based system, or a lotion.

9. A process for preparing a topical cosmetic composition, the process comprising:
i. dissolving diaminopyrimidine oxide in propylene glycol to obtain a first mixture;
ii. dissolving caffeine, and arginine to 1/3 rd part of water to the first mixture to obtain a second mixture;
iii. dissolving saw palmetto extract into the second mixture to obtain a third mixture;
iv. diluting methi extract with 1/3rd part of water and adding the diluted methi extract to the third mixture with stirring to obtain a fourth mixture;
v. adding gallic acid to the fourth mixture to obtain a fifth mixture;
vi. adding ethanol at a pH in a range of 4.3 to 4.4 to the fifth mixture and adjusting the pH to 5.5; and
vii. adding 1/3 rd of water to the pH adjusted mixture to obtain a topical composition.